GlassScriptPhysician profile
Ciara Veal
NPI 1558726778
$17,337.48
in general payments reported to CMS, 2019-2025
31 companies · $4,375 in 2025
The $4,375 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $826 · 2022: $2,127 · 2023: $5,040 · 2024: $4,970 · 2025: $4,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,213.73 |
| Education | $170.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,664.60 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,207.22 | 2021-2025 | Caplyta |
| Corium, LLC | $1,751.29 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $1,232.80 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Alkermes, INC. | $1,149.68 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,089.30 | 2021-2025 | Rexulti, Abilify Mycite |
| Bausch Health US, LLC | $874.12 | 2023-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $798.70 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $735.65 | 2021-2025 | Trintellix |
| Tris Pharma INC | $734.95 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Axsome Therapeutics, INC. | $662.06 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $587.43 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $375.36 | 2023-2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $372.12 | 2022-2024 | Jornay Pm |
| Almatica Pharma LLC | $337.16 | 2021-2025 | Loreev Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $267.78 | 2021-2025 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $265.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $237.54 | 2025 | Cobenfy |
| Indivior INC. | $185.50 | 2022-2023 | Sublocade, Perseris |
| Eisai INC. | $156.08 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $151.70 | 2024-2025 | Fanapt |
| Noven Therapeutics, LLC | $130.07 | 2021-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $85.91 | 2022-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $69.50 | 2022-2025 | Quviviq, Quviviq |
| Vertical Pharmaceuticals, LLC | $51.67 | 2024-2025 | Relexxii |
| Noven Pharmaceuticals, INC. | $39.07 | 2021-2023 | Xelstrym |
| Collegium Pharmaceutical, INC. | $38.10 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $23.78 | 2021 | |
| Acadia Pharmaceuticals INC | $22.47 | 2023 | Nuplazid |
| Adlon Therapeutics L.P. | $20.72 | 2021 | |
| Merck Sharp & Dohme LLC | $20.07 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciara Veal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.